Emerging markets — especially in **Southeast Asia (SEA) and other “pharmerging” regions — are among the fastest-growing areas of the global pharmaceutical and healthcare industry. Markets like Indonesia, Vietnam, Thailand, the Philippines and others are expected to expand rapidly over the next decade as access increases and demand grows. However, the conventional idea of “learning the market” — especially by just buying IQVIA reports — is not enough. In real life, successful Business...

Southeast Asia (SEA) offers compelling opportunities for pharmaceutical companies driven by growing healthcare demand, rising middle-class consumption and significant expansion across both prescription (Rx) and over-the-counter (OTC) segments. However, size alone is not a signal to enter every market or product category — and without disciplined strategic assessment, you risk regulatory bottlenecks, commercial underperformance and investments that underdeliver. A successful SEA market entry...

Business Development a high risk profession in pharma In recent years,   turnover among Business Development (BD) professionals in the pharmaceutical sector   has surged, reaching   20–30% annually in Europe and Asia . In other words,   one in four BD positions is replaced every year . 🔎   Compared with other industries: Technology: 18–22% Consulting: 15–20% General Industry: 10–12% This is alarming. BD in pharma is   mission-critical   — it opens doors in highly regulated markets, secures...